CBD and Pain

The Endocannabinoid System, Cannabinoids, and Painhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820295/

Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430692/

Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371734/

CBD and Inflammation

Cannabinoids as novel anti-inflammatory drugs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828614/

Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085542/

Antioxidative and Anti-Inflammatory Properties of Cannabidiol: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023045/

CBD and Anxiety

Cannabidiol as a Potential Treatment for Anxiety Disorders: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/

Cannabidiol in Anxiety and Sleep: A Large Case Series: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326553/

CBD and Arthritis

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851925/

CBD and Sleep

Cannabinoids, Endocannabinoids and Sleep: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388834/

Cannabidiol in Anxiety and Sleep: A Large Case Series: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326553/

CBD and Autoimmune diseases, MS

Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891926/

Cannabidiol to Improve Mobility in People with Multiple Sclerosis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874292/

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors - ScienceDirect: https://www.sciencedirect.com/science/article/pii/S0969996113001939

United States Patent #6630507

The United States of America as represented by the Department of Health and Human Services confirm in the US Patent #6630507 that “cannabinoids have been found to have antioxidant properties.”  The patent continues, “This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.”  Continuing, this patent states, “Nonpsychoactive cannabinoids, such as cannabidiol (CBD), are particularly advantageous to use because they avoid toxicity.”  The patent continues to confirm “No signs of toxicity or serious side effects have been observed following chronic administration of cannabidiol (CBD) to healthy volunteers, even in large acute doses of 700mg/day.”  The United States of America owns this patient and confirms “The present invention is believed to be particularly beneficial in the treatment of oxidative associated diseases of the CNS.”


Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021502/

The Pharmacological Case for Cannabigerol: https://pubmed.ncbi.nlm.nih.gov/33168643/

In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid: https://pubmed.ncbi.nlm.nih.gov/29986533/

Earn Rewards!